This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
14 Oct 2010

Banking on Blood

Long intervals have transpired between the first recognition of transfusion risk and the implementation of a preventive strategy.

Although remarkable advances have been made in the prevention of the major transfusion-transmitted diseases, long intervals have transpired between the first recognition of transfusion risk and the implementation of a preventive strategy.

For hepatitis B virus, that interval was 30 years; for non-A  non-B/hepatitis C virus, 15 years; and for human immunodeficiency virus, West Nile virus, Trypanosoma cruzi and bacteria, 3, 4, 5 and 18 years, respectively. In the existing reactive approach, there is a fundamental and inevitable delay before the government healthcare authorities can react; thus, infections are destined to occur. The continued emergence or re-emergence of transfusion-transmitted infections calls for a new paradigm of pre-emptive pathogen reduction (PR) and pathogen inactivation (PI).

New analysis from Frost & Sullivan (www.drugdiscovery.frost.com), European Blood Pathogen Inactivation Market, find

Related News